Sodium-glucose cotransporter 2 (SGLT2) inhibition with empagliflozin may stimulate erythropoiesis and improve functional iron deficiency in patients with type 2 diabetes and heart failure [88]. Here, SLC5A2 is linked to type 2 diabetes mellitus.